Carrie C Lubitz1, Konstantinos P Economopoulos2, Stephen Sy2, Colden Johanson2, Heike E Kunzel2, Martin Reincke2, G Scott Gazelle2, Milton C Weinstein2, Thomas A Gaziano2. 1. From the Departments of Surgery (C.C.L., K.P.E.) and Radiology (G.S.G.), Massachusetts General Hospital, Boston; Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (C.C.L., K.P.E., C.J., G.S.G.); Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA (S.S., G.S.G., M.C.W., T.A.G.); Schwerpunkt Endokrinologie, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, München, Germany (H.E.K., M.R.); and Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (T.A.G.). clubitz@partners.org. 2. From the Departments of Surgery (C.C.L., K.P.E.) and Radiology (G.S.G.), Massachusetts General Hospital, Boston; Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (C.C.L., K.P.E., C.J., G.S.G.); Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA (S.S., G.S.G., M.C.W., T.A.G.); Schwerpunkt Endokrinologie, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, München, Germany (H.E.K., M.R.); and Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (T.A.G.).
Abstract
BACKGROUND: Primary aldosteronism (PA) is a common and underdiagnosed disease with significant morbidity potentially cured by surgery. We aim to assess if the long-term cardiovascular benefits of identifying and treating surgically correctable PA outweigh the upfront increased costs in patients at the time patients are diagnosed with resistant hypertension (RH). METHODS AND RESULTS: A decision-analytic model compares aggregate costs and systolic blood pressure changes of 6 recommended or implemented diagnostic strategies for PA in a simulated population of at-risk RH patients. We also evaluate a 7th "treat all" strategy wherein all patients with RH are treated with a mineralocorticoid-receptor antagonist without further testing at RH diagnosis. Changes in systolic blood pressure are subsequently converted into gains in quality-adjusted life years (QALYs) by applying National Health and Nutrition Examination Survey data on concomitant risk factors to an existing cardiovascular disease simulation model. QALYs and lifetime costs were then used to calculate incremental cost-effectiveness ratios for the competing strategies. The incremental cost-effectiveness ratio for the strategy of computerized tomography (CT) followed by adrenal venous sampling (AVS) was $82,000/QALY compared with treat all. Incremental cost-effectiveness ratios for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective. Integrating differential patient-reported health-related quality of life adjustments for patients with PA, and incremental cost-effectiveness ratios for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained. CONCLUSIONS: CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with RH.
BACKGROUND: Primary aldosteronism (PA) is a common and underdiagnosed disease with significant morbidity potentially cured by surgery. We aim to assess if the long-term cardiovascular benefits of identifying and treating surgically correctable PA outweigh the upfront increased costs in patients at the time patients are diagnosed with resistant hypertension (RH). METHODS AND RESULTS: A decision-analytic model compares aggregate costs and systolic blood pressure changes of 6 recommended or implemented diagnostic strategies for PA in a simulated population of at-risk RH patients. We also evaluate a 7th "treat all" strategy wherein all patients with RH are treated with a mineralocorticoid-receptor antagonist without further testing at RH diagnosis. Changes in systolic blood pressure are subsequently converted into gains in quality-adjusted life years (QALYs) by applying National Health and Nutrition Examination Survey data on concomitant risk factors to an existing cardiovascular disease simulation model. QALYs and lifetime costs were then used to calculate incremental cost-effectiveness ratios for the competing strategies. The incremental cost-effectiveness ratio for the strategy of computerized tomography (CT) followed by adrenal venous sampling (AVS) was $82,000/QALY compared with treat all. Incremental cost-effectiveness ratios for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective. Integrating differential patient-reported health-related quality of life adjustments for patients with PA, and incremental cost-effectiveness ratios for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained. CONCLUSIONS: CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with RH.
Authors: David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey Journal: Circulation Date: 2008-06-24 Impact factor: 29.690
Authors: John W Funder; Robert M Carey; Carlos Fardella; Celso E Gomez-Sanchez; Franco Mantero; Michael Stowasser; William F Young; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-06-13 Impact factor: 5.958
Authors: Ankur Pandya; Stephen Sy; Sylvia Cho; Sartaj Alam; Milton C Weinstein; Thomas A Gaziano Journal: Med Decis Making Date: 2017-05-10 Impact factor: 2.583
Authors: Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke Journal: Curr Hypertens Rep Date: 2019-09-03 Impact factor: 5.369
Authors: Sabine C Käyser; Jaap Deinum; Wim Jc de Grauw; Bianca Wm Schalk; Hans Jhj Bor; Jacques Wm Lenders; Tjard R Schermer; Marion Cj Biermans Journal: Br J Gen Pract Date: 2018-01-15 Impact factor: 5.386
Authors: Jordana B Cohen; Debbie L Cohen; Daniel S Herman; John T Leppert; James Brian Byrd; Vivek Bhalla Journal: Ann Intern Med Date: 2020-12-29 Impact factor: 25.391